Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is expected to post Q3 2024 earnings per share of ($2.18)

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Free Report ) – Investment analysts at Zacks Small Cap issued their Q3 2024 EPS estimates for shares of Cadrenal Therapeutics in a research note issued on Monday, September 16th. Zacks Small Cap analyst D. Bautz expects that the company will earn ($2.18) per share for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($6.00) per share. Zacks Small Cap also issued estimates for Cadrenal Therapeutics Q4 2024 earnings at ($2.18) EPS, FY2024 earnings at ($8.17) EPS, FY2025 earnings at ($2.90) EPS and 2026 earnings at ($2.20) EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $0.20 price objective on shares of Cadrenal Therapeutics in a research report on Thursday, June 6th.

Check out our latest research report on cadherin therapy

Cadrenal Therapeutics trading rose 1.4%

Shares of NASDAQ:CVKD opened at $11.98 on Wednesday. Cadrenal Therapeutics has a 12-month low of $5.40 and a 12-month high of $32.55. The firm has a market cap of $191.78 million, a P/E ratio of -38.65 and a beta of 1.74.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Your Free Report ) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($2.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($19.04) by $16.79.

Cadrenal Therapeutics Company Profile

(Get a free report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company is focused on the development of Tecarfarina, a new oral and reversible anticoagulant to prevent heart attacks, strokes and deaths from blood clots in patients with rare cardiovascular conditions that require chronic anticoagulation, such as patients with ventricular assist devices left, end-stage renal disease. , atrial fibrillation and antiphospholipid thrombotic syndrome.

Recommended articles

Get news and reviews for Cadrenal Therapeutics daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cadrenal Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.